Omland Torbjørn, Sabatine Marc S, Jablonski Kathleen A, Rice Madeline Murguia, Hsia Judith, Wergeland Ragnhild, Landaas Sverre, Rouleau Jean L, Domanski Michael J, Hall Christian, Pfeffer Marc A, Braunwald Eugene
Department of Medicine, Akershus University Hospital, Lorenskog, Norway.
J Am Coll Cardiol. 2007 Jul 17;50(3):205-14. doi: 10.1016/j.jacc.2007.03.038. Epub 2007 Jun 29.
The purpose of this study was to assess the association between B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the incidence of specific cardiovascular events in low-risk patients with stable coronary disease, the incremental prognostic information obtained from these two biomarkers compared with traditional risk factors, and their ability to identify patients who may benefit from angiotensin-converting enzyme (ACE) inhibition.
The prognostic value of BNPs in low-risk patients with stable coronary artery disease remains unclear.
Baseline plasma BNP and NT-proBNP concentrations were measured in 3,761 patients with stable coronary artery disease and preserved left ventricular function participating in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibition) study, a placebo-controlled trial of trandolapril. Multivariable Cox regression was used to assess the association between natriuretic peptide concentrations and the incidence of cardiovascular mortality, fatal or nonfatal myocardial infarction, heart failure, and stroke.
The BNP and NT-proBNP levels were strongly related to the incidence of cardiovascular mortality, heart failure, and stroke but not to myocardial infarction. In multivariable models, BNP remained associated with increased risk of heart failure, whereas NT-proBNP remained associated with increased risk of cardiovascular mortality, heart failure, and stroke. By C-statistic calculations, BNP and NT-proBNP significantly improved the predictive accuracy of the best available model for incident heart failure, and NT-proBNP also improved the model for cardiovascular death. The magnitude of effect of ACE inhibition on the likelihood of experiencing cardiovascular end points was similar, regardless of either BNP or NT-proBNP baseline concentrations.
In low-risk patients with stable coronary artery disease and preserved ventricular function, BNPs provide strong and incremental prognostic information to traditional risk factors.
本研究旨在评估B型利钠肽(BNP)和N末端B型利钠肽原(NT-proBNP)与低风险稳定性冠心病患者特定心血管事件发生率之间的关联,这两种生物标志物与传统危险因素相比所获得的增量预后信息,以及它们识别可能从血管紧张素转换酶(ACE)抑制治疗中获益患者的能力。
BNP在低风险稳定性冠心病患者中的预后价值仍不明确。
在参与PEACE(血管紧张素转换酶抑制预防事件)研究(一项群多普利的安慰剂对照试验)的3761例稳定性冠心病且左心室功能保留的患者中,测量了基线血浆BNP和NT-proBNP浓度。采用多变量Cox回归评估利钠肽浓度与心血管死亡、致命或非致命性心肌梗死、心力衰竭和中风发生率之间的关联。
BNP和NT-proBNP水平与心血管死亡、心力衰竭和中风的发生率密切相关,但与心肌梗死无关。在多变量模型中,BNP仍与心力衰竭风险增加相关,而NT-proBNP仍与心血管死亡、心力衰竭和中风风险增加相关。通过C统计量计算,BNP和NT-proBNP显著提高了最佳可用模型对新发心力衰竭的预测准确性,NT-proBNP也改善了心血管死亡模型。无论BNP或NT-proBNP基线浓度如何,ACE抑制对发生心血管终点事件可能性的影响程度相似。
在低风险稳定性冠心病且心室功能保留的患者中,BNP为传统危险因素提供了强大的增量预后信息。